Literature DB >> 34059711

Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics.

Jesper R Nilsson1, Tom Baladi1,2,3, Audrey Gallud4,5, Dženita Baždarević6, Malin Lemurell2, Elin K Esbjörner4, L Marcus Wilhelmsson1, Anders Dahlén7.   

Abstract

To expand the antisense oligonucleotide (ASO) fluorescence labeling toolbox beyond covalent conjugation of external dyes (e.g. ATTO-, Alexa Fluor-, or cyanine dyes), we herein explore fluorescent base analogues (FBAs) as a novel approach to endow fluorescent properties to ASOs. Both cytosine and adenine analogues (tC, tCO, 2CNqA, and pA) were incorporated into a 16mer ASO sequence with a 3-10-3 cEt-DNA-cEt (cEt = constrained ethyl) gapmer design. In addition to a comprehensive photophysical characterization, we assess the label-induced effects on the gapmers' RNA affinities, RNA-hybridized secondary structures, and knockdown efficiencies. Importantly, we find practically no perturbing effects for gapmers with single FBA incorporations in the biologically critical gap region and, except for pA, the FBAs do not affect the knockdown efficiencies. Incorporating two cytosine FBAs in the gap is equally well tolerated, while two adenine analogues give rise to slightly reduced knockdown efficiencies and what could be perturbed secondary structures. We furthermore show that the FBAs can be used to visualize gapmers inside live cells using fluorescence microscopy and flow cytometry, enabling comparative assessment of their uptake. This altogether shows that FBAs are functional ASO probes that provide a minimally perturbing in-sequence labeling option for this highly relevant drug modality.

Entities:  

Year:  2021        PMID: 34059711     DOI: 10.1038/s41598-021-90629-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

Review 1.  The Medicinal Chemistry of Therapeutic Oligonucleotides.

Authors:  W Brad Wan; Punit P Seth
Journal:  J Med Chem       Date:  2016-07-29       Impact factor: 7.446

Review 2.  The current state and future directions of RNAi-based therapeutics.

Authors:  Ryan L Setten; John J Rossi; Si-Ping Han
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

Review 3.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

Review 4.  RNA-Targeted Therapeutics.

Authors:  Stanley T Crooke; Joseph L Witztum; C Frank Bennett; Brenda F Baker
Journal:  Cell Metab       Date:  2018-04-03       Impact factor: 27.287

5.  The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.

Authors:  Annemieke Aartsma-Rus; David R Corey
Journal:  Nucleic Acid Ther       Date:  2020-02-11       Impact factor: 5.486

6.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

7.  Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.

Authors:  M L Stephenson; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

Review 8.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

Review 9.  Locked nucleic acid: modality, diversity, and drug discovery.

Authors:  Peter H Hagedorn; Robert Persson; Erik D Funder; Nanna Albæk; Sanna L Diemer; Dennis J Hansen; Marianne R Møller; Natalia Papargyri; Helle Christiansen; Bo R Hansen; Henrik F Hansen; Mads A Jensen; Troels Koch
Journal:  Drug Discov Today       Date:  2017-10-06       Impact factor: 7.851

10.  Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay.

Authors:  Hans J Gaus; Ruchi Gupta; Alfred E Chappell; Michael E Østergaard; Eric E Swayze; Punit P Seth
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

View more
  1 in total

1.  7,8-Dihydro-8-oxo-1,N6-ethenoadenine: an exclusively Hoogsteen-paired thymine mimic in DNA that induces A→T transversions in Escherichia coli.

Authors:  Andrey V Aralov; Nina Gubina; Cristina Cabrero; Vladimir B Tsvetkov; Anton V Turaev; Bogdan I Fedeles; Robert G Croy; Ekaterina A Isaakova; Denis Melnik; Svetlana Dukova; Dmitriy Y Ryazantsev; Alexei A Khrulev; Anna M Varizhuk; Carlos González; Timofei S Zatsepin; John M Essigmann
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.